Editorial: The market won’t fix obscene insulin prices. It’s time for congressional action

Few issues within America’s dysfunctional health care system are more pressing than the astronomical price of insulin — access to which is, for millions of Americans, literally a matter of life or death. Congress is finally moving toward approving legislation that would partially address the problem. But passage will rely on the willingness of some hesitant Republicans, including Sen. Roy Blunt of Missouri, to set aside their free market absolutism and acknowledge that the apparent price-gouging going isn’t what markets are supposed to do.